Press release
Hyperlipidemia Therapeutics Pipeline Review 2018 - Clinical Trials, Results, Designations and Developments
Explore report sample at: https://www.psmarketresearch.com/market-analysis/hyperlipidemia-therapeutics-pipeline-analysis/report-sample
According to the research findings, a majority of the drug candidates for the treatment of hyperlipidemia are being developed to be administered by the oral route, which is convenient to take, and has been considered as non-invasive, often safer route that requires no special training to the patients.
It has been observed that most of the companies are developing drug candidates that involves novel target. Also, the drug candidates have showed positive efficacy in the clinical as well as Pre-Clinical stage of development. For instance, Inclisiran is under the Phase III stage of development by The Medicines Company for the treatment of hyperlipidemia. The drug candidate is an RNAi that targets proprotein convertase subtilisin/kexin type 9 (PCSK9) protein and RNA interference. It was found that Inclisiran cause sustained reductions in low-density lipoprotein (LDL) cholesterol levels over the course of 84 days in healthy volunteers.
Browse report at: https://www.psmarketresearch.com/market-analysis/hyperlipidemia-therapeutics-pipeline-analysis
Similarly, LY3015014 is under the Phase II stage of development by Eli Lilly and Company that target PCSK9 protein inhibitor. DCR-PCSK9 is a Pre-Clinical drug candidate of Dicerna Pharmaceuticals Inc.
Some of the key players involved in the development of hyperlipidemia therapeutics include Novartis AG, Eli Lilly and Company and Merck & Co. Inc.
About P&S Intelligence
P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hyperlipidemia Therapeutics Pipeline Review 2018 - Clinical Trials, Results, Designations and Developments here
News-ID: 1233662 • Views: …
More Releases from P&S Intelligence - Pharmaceuticals
Cyclin-Dependent Kinase Inhibitors Therapeutics Key Players Analysis - Merck, El …
The study analyzed that the CDK inhibitors therapeutics pipeline comprises approximately 24 drug candidates in different stages of development.
CDKs are the catalytic subunits of serine or threonine protein kinases that regulate the checkpoints in the cell cycle to control the proliferative capacity of cancerous cells. These proteins form cyclin-CDK complex which gets activated after phosphorylation, leading to cell proliferation.
Download report sample at: http://bit.ly/2eqiPu5
**Various collaborations for CDK inhibitors drug development
Eli Lilly…
Systemic Lupus Erythematosus Pipeline Analysis - Anthera Pharmaceuticals, Inc., …
The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates in different stages of development.
Explore report sample at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis/report-sample
Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues. The disease affects many parts of the body including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is caused by impaired immune system due to which the…
Herpes Simplex Virus Infections Therapeutic - Pipeline Analysis, Clinical Trials …
The study analysed that the Herpes simplex virus infections pipeline comprises of 20 drug candidates in different stages of development.
As per the findings of the research, most of the drug candidates are being developed to be administered by oral route.
Explore report sample at: https://www.psmarketresearch.com/market-analysis/hsv-infections-therapeutics-pipeline-analysis/report-sample
Many technologies are being developed that offer promising innovative treatments which can control the progression of Herpes simplex virus infections. The technologies include, but not limited to,…
Japanese Encephalitis Therapeutics - Pipeline Analysis, Clinical Trials, Patent …
Japanese encephalitis is a viral infection that spreads by mosquito bites. The study analyzed that the Japanese encephalitis therapeutics pipeline comprises approximately 12 drug candidates in different stages of development.
Explore report sample at: https://www.psmarketresearch.com/market-analysis/japanese-encephalitis-therapeutics-pipeline/report-sample
The companies developing drugs for the treatment of Japanese encephalitis are laying more emphasis on the drug candidates to be developed as vaccines, due to the promising results shown by these candidates the in the clinical development.…
More Releases for Hyperlipidemia
Top Trends Transforming the Hyperlipidemia Market Landscape in 2025: Revolutiona …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
What Will the Hyperlipidemia Industry Market Size Be by 2025?
The market size for hyperlipidemia has seen consistent growth over the previous years. Its projected expansion from $20.24 billion in 2024 to $21.03 billion in 2025, represents a compound annual growth rate (CAGR) of 3.9%. Factors contributing to this…
Elevating Demand In The Hyperlipidemia Market Driven By Rising Incidences Of Hea …
The Hyperlipidemia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Hyperlipidemia Market?
In the past few years, the hyperlipidemia market has experienced consistent growth. It is projected to increase from $20.24 billion in 2024 to $21.03 billion in 2025,…
Key Trend Reshaping the Hyperlipidemia Market in 2025: Revolutionary Advances in …
What industry-specific factors are fueling the growth of the hyperlipidemia market?
The prevalence of chronic ailments like heart disease is anticipated to drive the advancement of the hyperlipidemia market. Hyperlipidemia treatments are beneficial to individuals with heart conditions, as they lower heart attack risks, help in stroke prevention, enhance endothelial function, and minimize the requirement for invasive procedures. For example, the British Heart Foundation provided data in September 2024 citing that…
Prominent Hyperlipidemia Market Trend for 2025: Revolutionary Advances in Hyperl …
What Are the Projected Growth and Market Size Trends for the Hyperlipidemia Market?
The hyperlipidemia market is expected to grow from $20.24 billion in 2024 to $21.03 billion in 2025, at a CAGR of 3.9%. This growth is attributed to the increasing demand for effective treatments, growing public awareness, geographic expansion, and factors such as tobacco use.
The Hyperlipidemia market will grow to $24.3 billion by 2029 at a CAGR of 3.7%.…
Hyperlipidemia Treatment Market Size 2034
Hyperlipidemia Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Hyperlipidemia Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Hyperlipidemia Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Hyperlipidemia, historical and forecasted epidemiology as well…
Hyperlipidemia Market Trends 2024-2033: Outlook and Insights
"The Business Research Company recently released a comprehensive report on the Global Vanadium Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, the vanadium market size has grown…
